Table 1.
Patient demographics.
| Recurrent Ovarian Cancer Patients |
NanoString® Analysis Recurrent Ovarian Cancer Patients |
|
|---|---|---|
| Patients—no. | 21 | 12 |
| Age—years | ||
| Median | 61 | 61.5 |
| Mean | 59.8 | 59.6 |
| Range | 39–75 | 39–75 |
| <65—no. (%) | 16 (76.2) | 10 (83.3) |
| ≥65—no. (%) | 5 (23.8) | 2 (16.7) |
| No. of prior lines—no. (%) | ||
| Median | 2 | 2 |
| Mean | 2.95 | 3.17 |
| Range | 1–10 | 1–10 |
| CA-125 at time of treatment start—no. (%) | ||
| Median | 17.4 | 17.3 |
| Mean | 150.4 | 170.1 |
| Range | 17.4–1434 | 8.8–1434 |
| <35 | 11 (52.4) | 8 (66.7) |
| ≥35 | 4 (19.0) | 2 (16.7) |
| Missing | 6 (28.6) | 2 (16.7) |
| Disease at study start—no. (%) | ||
| No disease | 3 (14.3) * | 2 (16.7) * |
| disease | 18 (85.7) | 10 (83.3) |
* Patients had no evidence of disease (NED) (* two subjects with elevated CA-125, one subject with no visible disease by RECIST after 3rd line chemotherapy) prior to therapy for recurrence before enrolling in trial.